Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation

RR Razonable, RT Hayden - Clinical microbiology reviews, 2013 - Am Soc Microbiol
The negative impact of cytomegalovirus (CMV) infection on transplant outcomes warrants
efforts toward improving its prevention, diagnosis, and treatment. During the last 2 decades …

Cytomegalovirus

MV Dioverti, RR Razonable - Diagnostic Microbiology of the …, 2016 - Wiley Online Library
Cytomegalovirus (CMV), the fifth member of the human herpesvirus family, is one of the
largest viruses known to cause clinical disease. It is a double‐stranded DNA virus that …

Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial

AP Limaye, K Budde, A Humar, F Vincenti… - Jama, 2023 - jamanetwork.com
Importance Valganciclovir for 200 days is standard care for cytomegalovirus (CMV)
prophylaxis in high-risk CMV-seronegative kidney transplant recipients who receive an …

KDIGO clinical practice guideline on the evaluation and care of living kidney donors

KL Lentine, BL Kasiske, AS Levey, PL Adams… - …, 2017 - journals.lww.com
Abstract The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice
Guideline on the Evaluation and Care of Living Kidney Donors is intended to assist medical …

Cytomegalovirus in solid organ transplantation

RR Razonable, A Humar - American journal of transplantation, 2013 - amjtransplant.org
Cytomegalovirus (CMV) is a ubiquitousherpes virus that infects the majority of humans (1).
The seroprevalence rates of CMV ranges from 30–97%(2, 3). Primary infection manifests as …

[HTML][HTML] In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature …

RF Chemaly, JA Hill, S Voigt, KS Peggs - Antiviral Research, 2019 - Elsevier
Background Double-stranded (ds) DNA virus infections often occur concomitantly in
immunocompromised patients. We performed a systematic search of published in vitro …

Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine

DC Freed, Q Tang, A Tang, F Li, X He… - Proceedings of the …, 2013 - National Acad Sciences
Human cytomegalovirus (HCMV) can cause serious morbidity/mortality in transplant
patients, and congenital HCMV infection can lead to birth defects. Developing an effective …

Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus

DP Melendez, RR Razonable - Infection and drug resistance, 2015 - Taylor & Francis
Infection with cytomegalovirus is prevalent in immunosuppressed patients. In solid organ
transplant and hematopoietic stem cell transplant recipients, cytomegalovirus infection is …

Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects

D Kropeit, O von Richter, HP Stobernack… - … in drug development, 2018 - Wiley Online Library
Letermovir is being developed for human cytomegalovirus infection treatment and
prophylaxis. In patients receiving transplants, antivirals are coadministered with …

A multicenter case-control study of the effect of acute rejection and cytomegalovirus infection on pneumocystis pneumonia in solid organ transplant recipients

SM Hosseini-Moghaddam, M Shokoohi… - Clinical Infectious …, 2019 - academic.oup.com
Background Pneumocystis pneumonia (PCP) is associated with morbidity and mortality in
solid organ transplant (SOT) recipients. In this case-control study, we determined the …